唐氏综合征髓系白血病的临床与生物学特征
唐氏综合征患儿髓系白血病(ML-DS)常继发于短暂性异常髓系增生(TAM),国际研究已达成减强度化疗共识并获得良好结局。近20年研究揭示了GATA1突变等遗传与表观遗传特征,但复发机制不明且缺乏治疗共识。
要点
- ML-DS常继发于TAM,TAM为自限性胎儿肝脏来源巨核祖细胞扩增。
- 减强度化疗已获国际共识,ML-DS结局良好。
- GATA1突变可能与所有TAM和ML-DS病例相关。
核心结论
- ML-DS采用减强度化疗已获共识且结局良好,但复发机制不明、复发后结局差且无治疗共识,需未来重点研究。
研究设计与样本
- 基于多项国际研究和过去20年研究,综述唐氏综合征髓系白血病的临床与生物学特征。
主要发现
- 唐氏综合征患儿白血病风险升高,尤其是髓系白血病(ML-DS)。
- ML-DS常先有短暂性异常髓系增生(TAM),为自限性胎儿肝脏来源巨核祖细胞扩增。
- GATA1突变可能与所有TAM和ML-DS病例相关。
- 复发机制了解甚少,复发患者结局差且无治疗共识。
临床怎么用
- ML-DS治疗应采用减强度化疗方案。
- 复发ML-DS缺乏共识治疗,需个体化处理并探索新策略。
局限性
- 复发机制尚不清楚,缺乏复发治疗共识。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Children with Down syndrome are at an elevated risk of leukemia, especially myeloid leukemia (ML-DS). This malignancy is frequently preceded by transient abnormal myelopoiesis (TAM), which is self-limited expansion of fetal liver-derived megakaryocyte progenitors. An array of international studies has led to consensus in treating ML-DS with reduced-intensity chemotherapy, leading to excellent outcomes. In addition, studies performed in the past 20 years have revealed many of the genetic and epigenetic features of the tumors, including GATA1 mutations that are arguably associated with all cases of both TAM and ML-DS. Despite these advances in understanding the clinical and biological aspects of ML-DS, little is known about the mechanisms of relapse. Upon relapse, patients face a poor outcome, and there is no consensus on treatment. Future studies need to be focused on this challenging aspect of leukemia in children with DS.
引用
- Boucher AC, Caldwell KJ, Crispino JD, et al. Clinical and biological aspects of myeloid leukemia in Down syndrome. Leukemia. 2021. PMID: 34518645. doi:10.1038/s41375-021-01414-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。